Clinical Trial Update: A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness [Phase 2]

View source ↗

Summary

Phase 2 trial update on JZP-110 for Parkinson's disease with excessive daytime sleepiness assessing safety, efficacy, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Excessive Daytime Sleepiness
• Parkinson Disease

Drugs mentioned

• JZP-110

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Excessive Sleepiness, Parkinson Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-01-09